Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kliesch Sabine, Schmidt Stefanie, Wilborn Doris, Aigner Clemens, Albrecht Walter, Bedke Jens, Beintker Matthias, Beyersdorff Dirk, Bokemeyer Carsten, Busch Jonas, Classen Johannes, de Wit Maike, Dieckmann Klaus-Peter, Diemer Thorsten, Dieing Anette, Gockel Matthias, Göckel-Beining Bernt, Hakenberg Oliver W, Heidenreich Axel, Heinzelbecker Julia, Herkommer Kathleen, Hermanns Thomas, Kaufmann Sascha, Kornmann Marko, Kotzerke Jörg, Krege Susanne, Kristiansen Glen, Lorch Anja, Müller Arndt-Christian, Oechsle Karin, Ohloff Timur, Oing Christoph, Otto Ulrich, Pfister David, Pichler Renate, Recken Heinrich, Rick Oliver, Rudolph Yvonne, Ruf Christian, Schirren Joachim, Schmelz Hans, Schmidberger Heinz, Schrader Mark, Schweyer Stefan, Seeling Stefanie, Souchon Rainer, Winter Christian, Wittekind Christian, Zengerling Friedemann, Zermann D H, Zillmann Roger, Albers Peter
Аннотация
MATERIALS AND METHODS: An interdisciplinary panel of 42 experts including 1 patient representative developed the guideline content. Clinical recommendations and statements were based on scientific evidence and expert consensus. For this purpose, evidence tables for several review questions, which were based on systematic literature searches (last search in March 2018), were provided. Thirty-one experts, who were entitled to vote, rated the final clinical recommendations and statements.
RESULTS: Here we present the treatment recommendations separately for patients with metastatic seminoma and non-seminomatous GCT (stages IIA/B and IIC/III), for restaging and treatment of residual masses, and for relapsed and refractory disease stages. The recommendations also cover extragonadal and sex cord/stromal tumours, the management of follow-up and toxicity, quality-of-life aspects, palliative care, and supportive therapy.
CONCLUSION: Physicians and other medical service providers who are involved in the diagnostics, treatment, and follow-up of GCT (all stages, outpatient and inpatient care as well as rehabilitation) are the users of the present guideline. The guideline also comprises quality indicators for measuring the implementation of the guideline recommendations in routine clinical care; these data will be presented in a future publication.